Short-term treatment with rivastigmine and plasma levels of Ab peptides in Alzheimer’s disease
Journal Title: Folia Neuropathologica - Year 2005, Vol 43, Issue 4
Abstract
Deregulation of APP metabolism is considered to be a key pathogenic event in Alzheimer’s disease. Data from cell cultures indicate that the secretion of Ab1-42 might be inhibited by cholinesterase inhibitors, possibly via M1 receptors stimulation. Treatment with tacrine, a dual acetyl- and butyrylcholinesterase inhibitor, had no significant effect on mean plasma Ab species concentrations. However, a correlation was observed between higher drug concentrations and lower Ab levels that might indicate an effect on APP metabolism with an increased a-cleavage. Ab1-40 and Ab1-42 levels were measured in the plasma of 28 AD subjects by means of a commercially available ELISA before rivastigmine treatment and at week 2 after the first dose of the drug (3 mg/day) had been administered. Treatment with rivastigmine exhibited a significant effect on mean plasma concentrations of Ab1-42 (mean difference 7.8±8.4, t=-4.9, pmean difference 7.8±8.4, t=-4.9, p
Authors and Affiliations
Tomasz Sobow, Iwona Kloszewska
Keywords
Related Articles
- EP ID EP144326
- DOI -
- Views 86
- Downloads 0
The lower extremity nerve injuries – own experience in surgical treatment
The frequency of the lower extremity nerve injuries is assessed to about 20% of the overall lesions to the peripheral nerve system. Peroneal neuropathy is the most common lower extremity nerve palsy. In this study, resul...
The role of excitotoxicity in neurodegeneration
A body of evidence suggests that the mechanisms of excitotoxic neuronal damage evoked by excessive or prolonged activation of the excitatory amino acid receptors may be involved in pathogenesis of brain damage in acute i...
CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone)
The MCP-1 and RANTES levels were measured in 20 multiple sclerosis patients before and after 1 year daily treatment with 20 mg of subcutaneously applied glatiramer acetate. The level of MCP-1 in serum from multiple scler...
Neurodegeneration with brain iron accumulation
Neurodegeneration with brain iron accumulation (NBIA) describes a group of progressive extrapyramidal disorders with radiographic evidence of focal iron accumulation in the brain, usually in the basal ganglia. Patients p...
Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence
Prion diseases or transmissible spongiform encephalopathies (TSEs) are rare neurodegenerative disorders that can be acquired either by direct transmission, inherited through dominant mutations in the prion protein gene o...